Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus

doi:10.1016/j.ijantimicag.2012.03.010

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 食藥產業暨檢測科技系(含五專) > 期刊論文 > Item 310902800/27601

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/27601

標題:	Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus
作者:	Wang, Jiun-Ling Tang, Hung-Jen Hsieh, Pang-Hsin Chiu, Fang-Yao Chen, Yen-Hsu Chang, Ming-Chau Huang, Ching-Tai Liu, Chang-Pan Lau, Yeu-Jun Hwang, Kao-Pin Ko, Wen-Chien Wang, Chen-Ti Liu, Cheng-Yi Liu, Chien-Lin Hsueh, Po-Ren
貢獻者:	醫藥化學系
關鍵字:	Fusidic Acid Meticillin-Resistant Staphylococcus Aureus (Mrsa) Bone And Joint Infection Rifampicin Combination Therapy
日期:	2012-08
上傳時間:	2014-03-21 16:14:52 (UTC+8)
出版者:	Elsevier Science Bv
摘要:	There is a lack of surveillance data on resistance to fusidic acid (FA) in Asia, and no reviews of FA usage for the treatment of orthopaedic infections have been conducted since the year 2000. In this study, we present a systemic literature review of FA resistance in Asia and the clinical use of FA for the treatment of bone and joint infections (BJIs). The in vitro activity of FA against meticillin-resistant Staphylococcus aureus (MRSA) isolates remains good, with low (<10%) resistance rates in most Asian countries. FA in Asia appears to be a better oral anti-MRSA agent than trimethoprim/sulfamethoxazole and clindamycin. More than 80 cases of FA use for BJI have been reported since 2000 and the recurrence or failure rate is <10%. There is much evidence supporting the use of FA in combination with other antibiotics (e. g. rifampicin) as an oral treatment following intravenous glycopeptide treatment for BJIs. (C) 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
關聯:	International Journal of Antimicrobial Agents, 40(2), 103-107
显示于类别:	[食藥產業暨檢測科技系(含五專)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	1786	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....